Molecular effects of lithium

Molecular Interventions

Volumn 4, Issue 5, 2004, Pages 259-272

  Quiroz, Jorge A ^a   Gould, Todd D ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENYLATE CYCLASE; AMPHETAMINE; ANTICONVULSIVE AGENT; ARACHIDONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; FRUCTOSE BISPHOSPHATASE; GLYCOGEN SYNTHASE KINASE 3; INDOMETACIN; INOSITOL; INOSITOL PHOSPHATE; INOSITOL POLYPHOSPHATE; LITHIUM; MARCKS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NEUROLEPTIC AGENT; NUCLEOTIDASE; PHOSPHATIDYLINOSITIDE; PHOSPHOGLUCOMUTASE; PIROXICAM; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; TAMOXIFEN; UNINDEXED DRUG; VALPROIC ACID;

ARACHIDONIC ACID METABOLISM; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE EXACERBATION; DOWNSTREAM PROCESSING; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; INTRACELLULAR SPACE; MOOD DISORDER; NONHUMAN; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

BIPOLAR DISORDER; ENZYME INHIBITORS; HUMANS; LITHIUM; SIGNAL TRANSDUCTION;

EID: 7244239296     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.5.6     Document Type: Review

References (154)

1. Goodwin, F.K. and Ghaemi, S.N. The course of bipolar disorder and the nature of agitated depression. Am. J. Psychiatry 160, 2077-2079 (2003).
2. Judd, L.L. and Akiskal, H.S. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 73, 123-131 (2003).
3. Murray, C.J. and Lopez, A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
4. Schulz, R., Beach, S.R., Ives, D.G., Martire, L.M., Ariyo, A.A., and Kop, W.J. Association between depression and mortality in older adults: The Cardiovascular Health Study. Arch. Intem. Med. 160 1761-1768 (2000).
5. Musselman, D.L., Evans, D.L., and Nemeroff, C.B. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch. Gen. Psychiatry 55, 580-592 (1998).
6. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290, 1467-1473 (2003).
7. Baldessarini, R.J., Tondo, L., and Hennen, J. Lithium treatment and suicide risk in major affective disorders: Update and new findings. J. Clin. Psychiatry 64 Suppl. 5, 44-52 (2003).
8. 2+ competition for biomolecules. Anal. Biochem. 272, 1-7 (1999).
9. Ryves, W.J. and Harwood, A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280, 720-725 (2001).
10. Gould, T.D., Chen, G., and Manji, H.K. Mood stabilizer psychopharmacology. Clin. Neurosci. Res. 24, 193-212 (2002 ).
11. Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
12. +-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc. Natl. Acad. Sci. U.S.A. 92, 5149-5153 (1995).
13. Spiegelberg, B.D., Xiong, J.P., Smith, J.J., Gu, R.F, and York, J.D. Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3′-nucleotidase inhibited by inositol 1,4 bisphosphate. J. Biol. Chem. 274, 13619-13628 (1999).
14. Nordenberg, J., Kaplansky, M., Beery, E., Klein, S., and Beitner, R. Effects of lithium on the activities of phosphofructokinase and phosphoglucomutase and on glucose- 1,6-diphosphate levels in rat muscles, brain and liver. Biochem. Pharmacol. 31, 1025-1031 (1982).
15. Rhyu, G.I., Ray, W.J., Jr., and Markley, J.L. Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies. Biochemistry 23, 252-260 (1984).
16. Ray, W.J., Jr., Szymanki, E.S., and Ng, L. The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim. Biophys. Acta 522, 434-442 (1978).
17. Masuda, C.A., Xavier, M.A., Mattos, K.A., Galina, A., and Montero-Lomeli, M. Phosphoglucomutase is an in vivo lithium target in yeast. J. Biol. Chem. 276, 37794-37801 (2001).
18. Klein, P.S. and Melton, D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459 (1996).
19. Stambolic, V., Ruel, L., and Woodgett, J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr. Biol. 6, 1664-1668 (1996).
20. Gould, T.D., Zarate, C.A., and Manji, H.K. Glycogen synthase kinase-3: A target for novel bipolar disorder treatments. J. Clin. Psychiatry 65, 10-21 (2004).
21. Majerus, P.W. Inositol phosphate biochemistry. Annu. Rev. Biochem. 61, 225-250 (1992).
22. Gould, T.D. and Manji, H.K. Signaling networks in the pathophysiology and treatment of mood disorders. J. Psychosom. Res. 53, 687-697 (2002).
23. Gani, D., Downes., C.P., Batty, I., and Bramham, J. Lithium and myo-inositol homeostasis. Biochim. Biophys. Acta 1177, 253-269 (1993).
24. Naccarato, W.F., Ray, R.E., and Wells, W.W. Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes. Arch. Biochem. Biophys. 164, 194-201 (1974).
25. Hallcher, L.M. and Sherman, W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255, 10896-10901 (1980).
26. +-sensitive enzymes and proceeds via inositol 4-phosphate. Biochem. J. 249, 143-148 (1988).
27. Inhorn, R.C. and Majerus, P.W. Properties of inositol polyphosphate 1-phosphatase. J. Biol. Chem. 263, 14559-14565 (1988).
28. Berridge, M.J., Downes, C.P., and Hanley, M.R. Neural and developmental actions of lithium: A unifying hypothesis. Cell 59 411-419 (1989).
29. Berridge, M.J., Downes, C.P., and Hanley, M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206, 587-595 (1982).
30. Nahorski, S.R., Ragan, C.I., and Challiss, R.A. Lithium and the phosphoinositide cycle: An example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol. Sci. 12, 297-303 (1991).
31. Berry, G.T, Buccafusca, R., Greer, J.J., and Eccleston, E. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Mol. Genet. Metab. 82, 87-92 (2004).
32. Allison, J.H. and Stewart, M.A. Reduced brain inositol in lithium-treated rats. Nat. New Biol. 233, 267-268 (1971).
33. Atack, J.R. Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Bipolar medications: Mechanism of action. Belmaker, R.H. (ed.) Washington, DC: American Psychiatric Press, Inc. (2000).
34. Moore, G.J., Bebchuk, J.M., Parrish, J.K., Faulk, M.W., Arfken, C.L., Strahl-Bevacqua, J., and Manji, H.K. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiatry 156, 1902-1908 (1999).
35. Atack, J.R. Inositol monophosphatase inhibitors - lithium mimetics? Med. Res. Rev. 17, 215-24 (1997).
36. Atack, J.R., Cook, S.M., Watt, A.P., Fletcher, S.R., and Ragan, C.I. In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. 60, 652-658 (1993).
37. Atack, J.R., Prior, A.M., Fletcher, S.R., Quirk, K., McKernan, R., and Ragan, C.I. Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers. J. Pharmacol. Exp. Ther. 270 70-76 (1994).
38. Pollack, S.J., Atack, J.R., Knowles, M.R., McAllister, G., Ragan, C.I., Baker, R., Fletcher, S.R, Iversen, L.L., and Broughton, H.B. Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 5766-5770 (1994 ).
39. Bone, R., Springer, J.P., and Atack, J.R. Structure of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 10031-10035 (1992).
40. Frame, S. and Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16 (2001).
41. Woodgett, J.R. Judging a protein by more than its name: Gsk-3. Sci. STKE RE12 (2001).
42. Gould, T.D. and Manji, H.K. The wnt signaling pathway in bipolar disorder. Neuroscientist 8, 497-511 (2002).
43. Lenox, R.H., Gould, T.D., and Manji, H.K. Endophenotypes in bipolar disorder. Am. J. Med. Genet. 114, 391-406 (2002). [Erratum in: Am. J. Med. Genet. 114, 592 (2002).]
44. Jope, R.S. and Bijur, G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry 7 Suppl. 1, S35-S45 (2002).
45. Manji, H.K., Moore, G.J., and Chen, G. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46, 929-40 (1999).
46. Quiroz, J.A., Singh, J., Gould, TD., Denicoff, K.D., Zarate, C.A., and Manji, H.K. Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology. Mol Psychiatry 9, 756-776 (2004).
47. Chuang, D.M., Chen, R., Chalecka-Franaszek, E. et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 4, 129-136 (2002).
48. Kao, K.R., Masui, Y., and Elinson, R.P. Lithium-induced respecification of pattern in Xenopus laevis embryos. Nature 322 371-373 (1986).
49. He, X., Saint-Jeannet, J.P., Woodgett, J.R., Varmus, H.E., and Dawid, I.B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 375, 617-622 (1995).
50. Gurvich, N. and Klein, P.S. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96, 45-66 (2002).
51. Munoz-Montano, J.R., Moreno, F.J., Avila, J., and Diaz-Nido, J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188 (1997).
52. Gould, T.D., Chen, G., and Manji, H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38 (2004).
53. O'Brien, W.T., Harper, A.D., Jove, F, Woodgett, J.R., Maretto, S., Piccolo, S., and Klein, P.S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791-6798 (2004).
54. Phiel, C.J., Wilson, C.A., Lee, V.M., and Klein, P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439 (2003).
55. Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.M., Yamaguchi, H., and Takashima, A. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321, 61-64 (2002).
56. Su, Y., Ryder, J., Li, B. et al. Lithium, a common drug for Bipolar Disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry 43, 6899-6908 (2004).
57. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C.G., and Eldar-Finkelman, H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55, 781-784 (2004).
58. Gould, T.D., Einat, H., Bhat, R., and Manji, H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J. Neuropsychopharmacol. Jul 26, 1-4 (2004). [Epub ahead of print]
59. Li, X., Zhu, W., Roh, M.S., Friedman, A.B., Rosborough, K., and Jope, R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29, 1426-1431 (2004).
60. Beaulieu, J.M., Sotnikova, T.D., Yao, W.D., Kockeritz, L., Woodgett, J.R., Gainetdinov, R.R., and Caron, M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101, 5099-5104 (2004).
61. Kaidanovich, O. and Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opin. Ther. Targets 6, 555-561 (2002).
62. Bhat, R.V. and Budd, S.L. GSK3beta signalling: Casting a wide net in Alzheimer's disease. Neurosignals 11, 251-261 (2002 ).
63. Alvarez, G., Munoz-Montano, J.R., Satrustegui, J., Avila, J., Bogonez, E., and Diaz-Nido, J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 4 153-165 (2002).
64. Su, Y., Ryder, J., Li, B. et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899-6908 (2004).
65. Tong, H., Imahashi, K., Steenbergen, C., and Murphy, E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase - dependent pathway is cardioprotective. Circ. Res. 8, 377-379 (2002).
66. Frame, S., and Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16 (2001).
67. Ren, M., Senatorov, V.V., Chen, R.W, and Chuang, D.M. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc. Natl. Acad. Sci. U.S.A. 100, 6210-6215 (2003).
68. Bhat, R.V., Shanley, J., Correll, M.R, Fieles, W.E., Keith, R.A., Scott, C.W., and Lee, C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 97, 11074-11079 (2000).
69. Marcus, F. and Hosey, M.M. Purification and properties of liver fructose 1,6-bisphosphatase from C57BL/KsJ normal and diabetic mice. J. Biol. Chem. 255, 2481-2486 (1980).
70. Nakashima, K. and Tuboi, S. Size-dependent allosteric effects of monovalent cations on rabbit liver fructose- 1,6-bisphosphatase. J. Biol. Chem. 251, 4315-4321 (1976).
71. Villeret, V., Huang, S., Fromm, H.J., and Lipscomb, W.N. Crystallographic evidence for the action of potassium, thallium, and lithium ions on fructose-1,6-bisphosphatase. Proc. Natl. Acad. Sci. U.S.A. 92, 8916-8920 (1995).
72. Zhang, R., Villeret, V., Lipscomb, W.N., and Fromm, H. Kinetics and mechanisms of activation and inhibition of porcine liver fructose-1,6-bisphosphatase by monovalent cations. Biochemistry 35, 3038-3043 (1996).
73. Wright, S.W., Carlo, A.A., Danley, D.E. et al. 3-(2-carboxyethyl)-4,6-dichloro-1 H-indole-2-carboxylic acid: An allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg. Med. Chem. Lett. 13, 2055-2058 (2003).
74. Lopez-Coronado, J.M., Belles, J.M., Lesage, F., Serrano, R., and Rodriguez. P.L. A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3′-phosphoadenosine 5′-phosphate phosphatase and inositol-polyphosphate 1-phosphatase. J. Biol. Chem. 274, 16034-16039 (1999).
75. Yenush, L., Belles, J.M., Lopez-Coronado, J.M., Gil-Mascarell, R., Serrano, R., and Rodriguez, P.L. A novel target of lithium therapy. FEBS Lett. 467, 321-325 (2000).
76. Patel, S., Yenush, L., Rodriguez, P.L., Serrano, R., and Blundell, T.L. Crystal structure of an enzyme displaying both inositol-polyphosphate-1-phosphatase and 3′-phosphoadenosine-5′-phosphate phosphatase activities: A novel target of lithium therapy. J. Mol. Biol. 315, 677-685 (2002).
77. Agam, G. and Shaltiel, G. Possible role of 3′(2′)-phosphoadenosine-5′-phosphate phosphatase in the etiology and therapy of bipolar disorder. Prog. Neuropsychopharm. Biol. Psych. 27, 723-727 (2003).
78. Duman, R.S. Synaptic plasticity and mood disorders. Mol. Psychiatry 7 Suppl. 1, S29-S34 (2002).
79. Manji, H.K. and Duman, R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: Implications for the development of novel therapeutics. Psychopharmacol. Bull. 35, 5-49 (2001).
80. Einat, H., Yuan, P., Gould, T.D., Li, J., Du, J., Zhang, L., Manji, H.K., and Chen, G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311-7316 (2003).
81. Fukumoto, T, Morinobu, S., Okamoto, Y., Kagaya, A., and Yamawaki, S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 158, 100-106 (2001).
82. Angelucci, F., Aloe, L., Jimenez-Vasquez, P., and Mathe, A.A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line - derived neurotrophic factor in a rat model of depression. Int. J. Neuropsychopharmacol. 6, 225-231 (2003).
83. Jope, R.S. A bimodal model of the mechanism of action of lithium. Mol. Psychiatry 4, 21-25 (1999).
84. Kofman, O., Li, P.P., and Warsh, J.J. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol. Biochem. Behav. 59, 191-200 (1998).
85. Extein, I., Tallman, J., Smith, C.C., and Goodwin, F.K. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res. 191-197 (1979).
86. Ebstein, R.P., Oppenheim, G., Ebstein, B.S., Amiri, Z., and Stessman, J. The cyclic AMP second messenger system in man: The effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 323-353 (1986).
87. Wang. J.-F, Young, L.T, Li, P.P., and Warsh, J.J. Signal transduction abnormalities in bipolar disorder. In: Bipolar disorder: Biological Models and Their Clinical Application. Joffe, R.T. (ad.) New York: Dekker, 41-79 (1997).
88. Dessauer, C.W., Tesmer, J.J., Sprang, S.R., and Gilman, A.G. The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol. Sci. 20, 205-210 (1999).
89. Iwatsubo, K., Tsunematsu, T., and Ishikawa, Y. Isoform-specific regulation of adenylyl cyclase: A potential target in future pharmacotherapy. Expert Opin. Ther. Targets 7, 441-451 (2003).
90. Soderling, T.R. CaM-kinases: Modulators of synaptic plasticity. Curr. Opin. Neurobiol. 10, 375-380 (2000).
91. Manji, H.K. and Lenox, R.H. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry 46, 1328-1351 (1999).
92. van Calker, D. and Belmaker, R.H. The high affinity inositol transport system - implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord. 2, 102-107 (2000).
93. Lubrich, B. and van Calker, D. Inhibition of the high affinity myo-inositol transport system: A common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21, 519-529 (1999).
94. Williams, R.S., Cheng, L., Mudge, A.W., and Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295 (2002).
95. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614 (1992).
96. Manji, H.K., Bersudsky, Y., Chen, G., Belmaker, R.H., and Potter, W.Z. Modulation of protein kinase C isozymes and substrates by lithium: The role of myo-inositol. Neuropsychopharmacology 15 370-381 (1996).
97. Manji, H.K., Etcheberrigaray, R., Chen, G., and Olds, J.L. Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme. J. Neurochem. 61, 2303-2310 (1993).
98. Li, X. and Jope, R.S. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells. J. Neurochem. 65, 2500-2508 (1995).
99. Lenox, R.H., Watson, D.G., Patel, J., and Ellis, J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570, 333-340 (1992).
100. Watson, D.G., and Lenox, R.H. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: Potentiation by muscarinic receptor activation. J. Neurochem. 67, 767-777 (1996).
101. Post, R.M., Susan, R., and Weiss, B. Sensitization, kindling, and carbamazepine: An update on their implications for the course of affective illness, in Pharmacopsychiatry 25, 41-43 (1992).
102. Einat, H., Manji H.K., and Belmaker, R.H. New approaches to modeling bipolar disorder. Psychopharm. Bull. 37, 47-63 (2003).
103. Daigen, A., Akiyama, K., Itoh, T, Kohira, I., Sora, I., Morimoto, K., and Otsuki, S. Long-lasting enhancement of the membrane-associated protein kinase C activity in the hippocampal-kindled rat. Jpn. J. Psychiatry Neurol. 45, 297-301 (1991).
104. Kohira, I., Akiyama, K., Daigen, A., Itoh, T., Ono, M., Morimoto, K., Sora, I., and Otsuki, S. Permanent increase in membrane-associated protein kinase C activity in the hippocampal-kindled rat. Jpn. J. Psychiatry Neurol. 46, 510-512 (1992).
105. Osonoe, K., Ogata, S., Iwata, Y., and Mori, N. Kindled amygdaloid seizures in rats cause immediate and transient increase in protein kinase C activity followed by transient suppression of the activity. Epilepsia 35, 850-854 (1994).
106. Ono, M., Akiyama, K., Tsutsui, K., and Kuroda, S. Differential changes in the activities of multiple protein kinase C subspecies in the hippocampal-kindled rat. Brain Res. 660, 27-33 (1994).
107. Akiyama, K., Ono, M., Kohira, I., Daigen, A., Ishihara, T., and Kuroda, S. Long-lasting increase in protein kinase C activity in the hippocampus of amygdala-kindled rat. Brain Res. 679, 212-220 (1995).
108. Kamphuis, W., Hendriksen, E., and Lopes da Silva, F.H. Isozyme-specific changes in the expression of protein kinase C isozyme (alpha-zeta) genes in the hippocampus of rats induced by kindling epileptogenesis. Brain Res. 702, 94-100 (1995).
109. Beldhuis, H.J., Everts, H.G, Van der Zee, E.A., Luiten, P.G., and Bohus, B. Amygdala kindling-induced seizures selectively impair spatial memory. 1. Behavioral characteristics and effects on hippocampal neuronal protein kinase C isoforms. Hippocampus 2, 397-409 (1992).
110. Chen, S.J., Desai, M.A., Klann, E., Winder, D.G., Sweatt, J.D., and Conn, P.J. Amygdala kindling alters protein kinase C activity in dentate gyrus. J. Neurochem. 59, 1761-1769 (1992).
111. Buzsaki, G., Hsu, M., Horvath, Z., Horsburgh, K., Sundsmo, M., Masliah, E., and Saitoh, T. Kindling-induced changes of protein kinase C levels in hippocampus and neocortex. Epilepsy Res. Suppl. 9, 279-283 (1992).
112. Beldhuis, H.J., De Ruiter, A.J., Maes, F.W., Suzuki, T, and Bohus, B. Long-term increase in protein kinase C-gamma and muscarinic acetylcholine receptor expression in the cerebral cortex of amygdala-kindled rats - a quantitative immunocytochemical study. Neuroscience 55, 965-973 (1993).
113. Giambalvo, C.T. Protein kinase C and dopamine transport-2. Effects of amphetamine in vitro. Neuropharmacology 31, 1211-1222 (1992).
114. Giambalvo, C.T. Protein kinase C and dopamine transport-1. Effects of amphetamine in vivo. Neuropharmacology, 31, 1201-1210 (1992).
115. Gnegy, M.E., Hong, P., and Ferrell, S.T. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res. Mol. Brain Res. 20, 289-298 (1993).
116. Iwata, S.I., Hewlett, G.H., Ferrell, S.T., Kantor, L., and Gnegy, M.E. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J. Pharmacol. Exp. Ther. 283, 1445-1452 (1997).
117. Iwata, S., Hewlett, G.H., and Gnegy, M.E. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 26, 281-291 (1997).
118. Kantor, L. and Gnegy, M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J. Pharmacol. Exp. Ther. 284, 592-598 (1998).
119. Steketee, J.D. Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: Behavioral and in vivo microdialysis studies. Neuropharmacology 32, 1289-1297 (1993).
120. Steketee, J.D. Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 6, 69-72 (1994).
121. Bebchuk, J.M., Arfken, C.L., Dolan-Manji, S., Murphy, J., Hasanat, K., and Manji, H.K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57, 95-97 (2000).
122. Du, J., Gould, T.D., and Manji, H.K. Neurotrophic signaling in mood disorders. In: Signal Transduction and Human Disease. Gutkind, J.S. (ed.) Hoboken, NJ: John Wiley & Sons, Inc., 411-446 (2003).
123. Trentani, A., Kuipers, S.D., Ter Horst, G.J., and Den Boer, J.A. Selective chronic stress-induced in vivo ERK1/2 hyperphosphorylation in medial prefrontocortical dendrites: Implications for stress-related cortical pathology? Eur. J. Neurosci. 15, 1681-1691 (2002).
124. DeVries, A.C., Joh, H.D., Bernard, O., Hattori, K., Hurn, P.D., Traystman, R.J., and Alkayed, N.J. Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc. Natl. Acad. Sci. U.S.A. 98, 11824-11828 (2001).
125. Yuan, P.X., Huang, L.D., Jiang, Y.M., Gutkind, J.S., Manji, H.K., and Chen, G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276, 31674-31683 (2001).
126. Chen, G., Zeng, W.Z., Yuan, P.X., Huang, L.D., Jiang, Y.M., Zhao, Z.H., and Manji, H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72, 879-882 (1999).
127. Manji, H.K. and Chen, G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry 7 Suppl.1, S46-S56 (2002).
128. Chen, G., Huang, L.D., Zeng, W.Z., and Manji, H.K. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: Long-term effects on cell survival and transcript stability. Int. J. Neuropsychopharmacol. 4, 47-64 (2001).
129. Rajkowska, G. Histopathology of the prefrontal cortex in major depression: What does it tell us about dysfunctional monoaminergic circuits? Prog. Brain Res. 126, 397-412 (2000).
130. Huang, X., Wu, D.Y., Chen, G., Manji, H., and Chen, D.F. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 44, 347-354 (2003).
131. Hashimoto, R., Takei, N., Shimazu, K., Christ, L., Lu, B., and Chuang, D.M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173-1179 (2002).
132. Drevets, W.C., Price, J.L., Simpson, J.R., Jr., Todd, R.D., Reich, T., Vannier, M., and Raichle, M.E. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824-827 (1997 ).
133. Bowley, M.P., Drevets, W.C., Ongur, D., and Price, J.L. Low glial numbers in the amygdala in major depressive disorder. Biol. Psychiatry 52, 404-412 (2002).
134. Tsai, G. and Coyle, J.T. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46, 531-540 (1995).
135. Moore, G.J., Bebchuk, J.M., Hasanat, K. et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol. Psychiatry 48, 1-8 (2000).
136. Moore, G.J., Bebchuk, J.M., Wilds, I.B., Chen, G., and Manji, H.K. Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242 (2000).
137. Sassi, R., Nicoletti, M., Brambilla, P., Mallinger, A., Frank, E., Kupfer, D., Keshavan, M., and Soares, J. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 329, 243 (2002).
138. Silverstone, P.H., Wu, R.H., O'Donnell, T., Ulrich, M., Asghar, S.J., and Hanstock, C.C. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int. Clin. Psychopharmacol. 18, 73-79 (2003).
139. 2 via GTP-binding proteins: Arachidonic acid and its metabolites as second messengers. Trends Neurosci. 11, 117-123 (1988).
140. Rapoport, S.I. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J. Mol. Neurosci. 16, 243-261 (2001).
141. Axelrod, J. Phospholipase A2 and G proteins. Trends Neurosci. 18, 64-65 (1995).
142. Chang, M.C., Contreras, M.A., Rosenberger, T.A., Rintala, J.J., Bell, J.M., and Rapoport, S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: A possible common effect of mood stabilizers. J. Neurochem. 77, 796-803 (2001).
143. Chang, M.C., Grange, E., Rabin, O., Bell, J.M., Allen, D.D., and Rapoport, S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 220, 171-174 (1996). Erratum in: Neurosci. Lett. 222, 141 (1997).
144. Rapoport, S.I. and Bosetti, F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596 (2002).
145. 2 activity. Neurochem. Res. 23 887-892 (1998).
146. 2 is a target for chronic lithium in rat brain. Neuroreport 10, 3887-3890 (1999).
147. 2 concentration in rat brain. Mol. Psychiatry 7, 845-850 (2002).
148. Bosetti, F., Weerasinghe, G.R., Rosenberger, T.A., and Rapoport, S.I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem. 85, 690-696 (2003).
149. 2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry, 56, 248-254 (2004).
150. Ross, B.M., Brooks, R.J., Lee, M., Kalasinsky, K.S., Vorce, S.P., Seeman, M., Fletcher, P.J., and Turenne, S.D. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur. J. Pharmacol. 450, 141-151 (2002).
151. Reid, M.S., Ho, L.B., Hsu, K., Fox, L., Tolliver, B.K., Adams, J.U., Franco, A., and Berger, S.P. Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization. Pharmacol. Biochem. Behav. 71, 37-54 (2002).
152. Madrigal, J.L., Moro, M.A., Lizasoain, I., Lorenzo, P., Fernandez, A.P., Rodrigo, J., Bosca, L., and Leza, J.C. Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 28, 1579-1588 (2003).
153. Soares, J. and Bowden, C. March treatment trial grant. Stanley Medical Institute. www.stanleyresearch.org (2002).
154. Gould, T.D., Quiroz, J.A., Singh, J., Zarate, C.A., and Manji, H.K. Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry 9, 734-755 (2004).